Home
About
Pricing
Log In
Back
FRGG
Asset Logo

Franklin Global Growth Fund - Active ETF

πŸ‡¦πŸ‡Ί ASX

πŸ›οΈ CONSUMER

πŸ€– TECHNOLOGY

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ“™ Holdings

πŸ’° Distributions

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

-7.57%
Annual Growth

1 years average annual capital growth

πŸ’°

21.89%
Annual distribution yield

Based on the most recent distribution

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

2
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

FRGG.AX was created on 2024-04-15 by Franklin. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the MSCI World ex Australia Index NR, in Australian dollar terms after fees and expenses (but before taxes), over the medium to longer term.

🌐 Website

πŸ“ˆ Performance

Price History

-10.42%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ“™ Top Holdings

Show more
Synopsys Inc
4.30%

Amadeus IT Group SA

4.14%

DSV AS

3.84%

Sika AG

3.72%

Updated as of 30 June 2025

Industry Exposure
πŸ€– Information
42%
πŸ›οΈ Consumer
21%
🏭 Industrials
19%
🏦 Financials
18%
🧱 Materials
10%

πŸ’° Distributions

Payouts

πŸ’° Annual Distribution Yield*

21.89%

πŸ’° Annual Distribution Earnings Per $1,000 invested**

$218.86

πŸ’° Most Recent Distribution Franked Percentage Estimate

0.00%

πŸ’° Average Distribution Franked Percentage Estimate

0.00 %

πŸ’° Distribution reinvestment

Learn more

* Based on the most recent distribution

** Calculated by multiplying the most recent distribution yield by $1,000

Estimate your distribution

If you held

$

of FRGG, your last distribution payment(s) would have been:

$ 1,839.81

on Thu Jul 10 2025

$ 0

on Mon Jan 13 2025

*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.

Distribution History

1Y

5Y

10Y

Graph

Table

Year
Yearly Distribution Earnings Per Share
Franking Estimate

2025

$0.00

0.00%

2024

$0.12

0.00%

2023

$0.00

0.00%

2022

$0.00

0.00%

2021

$0.00

0.00%

2020

$0.00

0.00%

2019

$0.00

0.00%

2018

$0.00

0.00%

2017

$0.00

0.00%

2016

$0.00

0.00%

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

0.90%
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$2.15

πŸ’° Price To Earnings Ratio

0.00

πŸ’° Price To Book Ratio

0.00

πŸ’° Leveraged

No

πŸ’° Inverse

No

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in FRGG

2

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

10 weeks

πŸ’΅ Average investment amount

$1,501

⏰ Last time a customer invested in FRGG

15 days
FRGG investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

100%
πŸ‘Ά Age of investors

18 - 25

50%

26 - 34

50%

35 - 90

πŸ™‹ Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in FRGG also invest in...

Vanguard Ethically Conscious International Shares Index ETF

VESG

VESG.AX was created on 2018-09-11 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious International Shares Index ETF seeks to track the return of the FTSE Developed ex Australia Choice Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax

πŸ™Œ Performance (5Yr p.a)

16.54%

πŸ“Š Share price

$108.00 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Find Out More

VISM.AX was created on 2018-11-09 by Vanguard. The fund's investment portfolio concentrates primarily on small cap equity. The Vanguard MSCI International Small Companies Index ETF seeks to track the return of the MSCI World ex-Australia Small Cap Index in Australian dollars, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

9.46%

πŸ“Š Share price

$72.55 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

16.64%

πŸ“Š Share price

$148.16 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

21.37%

πŸ“Š Share price

$66.26 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

19.29%

πŸ“Š Share price

$53.35 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ€– TECHNOLOGY

πŸ‡ΊπŸ‡Έ UNITED STATES

Want more shares? Try these...

Finbar Group Ltd. engages in the provision of development of medium to high density residential apartments and commercial property. The company is headquartered in Perth, Western Australia and currently employs 28 full-time employees. The firm is focused on the development of medium to high-density residential buildings and commercial developments in Western Australia by way of direct ownership, ownership through fully owned subsidiaries or by equity accounted investees. Its segments include Residential Apartment Development, Commercial Office/Retail development, and Rental of Property. Its segments are all located in West Australia. The Company’s completed projects include AT238, Vue Tower, One Kennedy, Dianella Apartments and REVA. Its under construction projects include Civic Heart, Aurora Applecross and The Point. The firm holds its rental properties through 175 Adelaide Terrace Pty Ltd, 31 Rowe Avenue Pty Ltd, 32 Riversdale Road Pty Ltd, 36 Chester Avenue Pty Ltd, 43 McGregor Road Pty Ltd, 5-7 Harper Terrace Pty Ltd, Finbar Karratha Pty Ltd and Finbar Commercial Pty Ltd.

πŸ™Œ Performance (5Yr p.a)

1.40%

πŸ“Š Share price

$0.69 AUD

🏠 REAL ESTATE

Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold. The firm has developed a povidone-iodine nasal spray, called Nasodine Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the United States, Europe and Australia. The firm has also completed six clinical trials for Nasodine, including a Phase I study, three Phase II studies and two Phase III studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Nasodine Phase II COVID-19 trail achieves primarily endpoints.

πŸ“Š Share price

$0.07 AUD

πŸ“¦ LOGISTICS

Compare
Add to watchlist